BAYZF News and Press, Bayer AG Registered Shares From 01/08/24

2024-01-08 14:06:31 ET Disclosing its preliminary financials for Q4 2023, Regeneron Pharmaceuticals ( NASDAQ: REGN ) announced Monday that it intends to recognize ~$1.34B as U.S. net product sales from its blockbuster eye disease therapy Eylea during the quarter. Meanwhile, its ...

2024-01-06 07:15:00 ET Summary High dividend yield companies are essential components within a well-balanced and diversified dividend portfolio, particularly for those seeking to generate substantial additional income via dividends. In this article, I will present 10 high dividend...

2024-01-04 15:25:59 ET More on Recursion Pharmaceuticals Recursion Pharmaceuticals: Second Half 2024 Data Readouts Are Major Inflection Points Absci hits new 52-week high as race for AI drug discovery heats up Recursion Pharma spikes after 3.8M ARK buy Seekin...

2023-12-23 22:50:39 ET More on Bayer AG Bayer Isn't Dead Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Monsanto told to pay $857 million over PCBs at school in Washington Bayer divestiture of ...

2023-12-22 18:18:15 ET Summary Today, we revisit Bicycle Therapeutics plc, a UK-based clinical stage biotech company focused on developing medicines for underserved diseases. The company has inked two significant collaboration deals with large drug makers in 2023 and continues to ...

2023-12-22 17:56:28 ET Summary The biotech bear market has presented investment opportunities for investors to take meaningful stakes in public companies at venture valuations. AI drug discovery has faced setbacks in the past 18 months, but Gain Therapeutics' has found success usi...

2023-12-18 16:08:20 ET More on Bayer, Bayer AG, etc. Bayer Isn't Dead Breaking Up Bayer? Probably Not! Bayer Aktiengesellschaft 2023 Q3 - Results - Earnings Call Presentation Bayer divestiture of consumer health business would cause huge tax bill - report ...

2023-12-06 13:21:55 ET Summary Bayer AG's financial results show weakness, primarily due to temporary impact from its crop sciences business. Despite challenges, the company's outlook predicts continued respectable performance. Bayer's consumer health business remains strong, ...

2023-12-05 10:30:35 ET Summary EyePoint Pharmaceuticals, Inc. EYP-1901, a potential treatment for wet age-related macular degeneration, showed positive results in a Phase 2 study, meeting primary and secondary endpoints. The drug demonstrated non-inferiority to the current standar...

2023-11-29 15:03:50 ET Prominent activist investor Jeff Ubben is shutting down his social investing-focused firm, Inclusive Capital Partners. Inclusive Capital has started to wind down its operations and is returning capital to limited partners, acording to a WSJ report on Wednesday...